PT1344533E - Composições farmacêuticas compreendendo lectina de ligação a manose - Google Patents

Composições farmacêuticas compreendendo lectina de ligação a manose Download PDF

Info

Publication number
PT1344533E
PT1344533E PT03388016T PT03388016T PT1344533E PT 1344533 E PT1344533 E PT 1344533E PT 03388016 T PT03388016 T PT 03388016T PT 03388016 T PT03388016 T PT 03388016T PT 1344533 E PT1344533 E PT 1344533E
Authority
PT
Portugal
Prior art keywords
mbl
composition
gly
leu
ser
Prior art date
Application number
PT03388016T
Other languages
English (en)
Portuguese (pt)
Inventor
Jesper Lund Larsen
Leif Kongerslev
Original Assignee
Natimmune As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natimmune As filed Critical Natimmune As
Publication of PT1344533E publication Critical patent/PT1344533E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT03388016T 2002-03-15 2003-03-14 Composições farmacêuticas compreendendo lectina de ligação a manose PT1344533E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200200414 2002-03-15

Publications (1)

Publication Number Publication Date
PT1344533E true PT1344533E (pt) 2007-01-31

Family

ID=27763313

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03388016T PT1344533E (pt) 2002-03-15 2003-03-14 Composições farmacêuticas compreendendo lectina de ligação a manose

Country Status (11)

Country Link
US (1) US7462596B2 (cg-RX-API-DMAC7.html)
EP (1) EP1344533B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005526084A (cg-RX-API-DMAC7.html)
CN (1) CN1652813A (cg-RX-API-DMAC7.html)
AT (1) ATE337014T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003215524A1 (cg-RX-API-DMAC7.html)
DE (1) DE60307701T2 (cg-RX-API-DMAC7.html)
DK (1) DK1344533T3 (cg-RX-API-DMAC7.html)
ES (1) ES2271515T3 (cg-RX-API-DMAC7.html)
PT (1) PT1344533E (cg-RX-API-DMAC7.html)
WO (1) WO2003077937A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー/エス 修飾glp−1の安定な処方剤
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー/エス 安定化された薬学的ペプチド組成物
KR101308912B1 (ko) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US7335633B2 (en) * 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
EP1618887A1 (en) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Clearance of polyols from the body
WO2006024631A2 (en) 2004-08-31 2006-03-09 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
JP5175103B2 (ja) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー/エス 安定なペプチド製剤
KR100770362B1 (ko) * 2004-12-30 2007-10-26 (주)두비엘 분무건조 고분자형 콜렉틴족 단백질 및 그의 제조방법
EP1874333A2 (en) * 2005-04-11 2008-01-09 Natimmune A/S Mannan-binding lectin (mbl) in the treatment of immunocompromised conditions asssociated with cancer
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
WO2007102736A2 (en) * 2006-03-08 2007-09-13 Universitair Medisch Centrum Utrecht Interfering in activation of an immune cell by influencing interaction of lair and collagen.
CA2736563C (en) * 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
CN102712687A (zh) 2009-07-17 2012-10-03 丹麦国家医院 作为补体激活的抑制剂的masp同种型
US9150631B2 (en) 2010-01-19 2015-10-06 President And Fellows Of Harvard College Engineered opsonin for pathogen detection and treatment
RU2591823C2 (ru) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
EP3081937B1 (en) 2011-07-18 2019-11-13 President and Fellows of Harvard College Engineered microbe-targeting molecules and uses thereof
US9632085B2 (en) 2012-02-29 2017-04-25 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
DK2861246T3 (en) * 2012-06-18 2021-04-26 Omeros Corp Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
EP2976642A4 (en) 2013-03-15 2016-09-21 Harvard College METHOD AND COMPOSITIONS FOR IMPROVING THE DETECTION AND / OR RECORDING OF A TARGET UNIT
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
JP6649250B2 (ja) 2013-05-21 2020-02-19 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたヘム結合性構成物およびその使用
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
EP3763378A1 (en) 2015-08-06 2021-01-13 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
CN110755601B (zh) * 2019-10-31 2023-06-23 云南康洲生物科技有限公司 一种治疗hiv/aids免疫重建缺陷的芸豆凝集素植物药组合物和制备方法及其应用
KR20220143036A (ko) 2020-02-18 2022-10-24 노보 노르디스크 에이/에스 약학적 제형
AU2021466116A1 (en) * 2021-10-01 2024-04-11 Faculty Of Chemistry Carbohydrate binding polypeptide of savalia savaglia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE336504T1 (de) * 1998-06-10 2006-09-15 Statens Seruminstitut Reinigungsverfahren zur herstellng von mannan bindendem lectin (mbl) und mbl enthaltende medizinische zubereitung
US6429192B1 (en) * 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6297024B1 (en) * 1998-10-15 2001-10-02 Cell Activation, Inc. Methods for assessing complement activation
CA2372128A1 (en) * 1999-05-14 2000-11-23 Steffen Thiel Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin

Also Published As

Publication number Publication date
DK1344533T3 (da) 2007-01-08
CN1652813A (zh) 2005-08-10
DE60307701T2 (de) 2007-10-11
EP1344533B1 (en) 2006-08-23
ATE337014T1 (de) 2006-09-15
DE60307701D1 (de) 2006-10-05
US20040006009A1 (en) 2004-01-08
WO2003077937A1 (en) 2003-09-25
US7462596B2 (en) 2008-12-09
AU2003215524A1 (en) 2003-09-29
ES2271515T3 (es) 2007-04-16
EP1344533A1 (en) 2003-09-17
JP2005526084A (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
PT1344533E (pt) Composições farmacêuticas compreendendo lectina de ligação a manose
JP4879104B2 (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子ix処方
ES2725449T3 (es) Composición de factor VII
BRPI0821474B1 (pt) Formulação farmacêutica líquida estável
KR20050013148A (ko) 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
CA3054718A1 (en) C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency
JP2010513462A (ja) 第VIIおよび第VIIa因子組成物
US20190231855A1 (en) Compositions of human prothrombin and activated factor x for improving hemostasis in the treatment of bleeding disorders
JP6516855B2 (ja) C1エステラーゼ阻害剤の医薬製剤
JP2007513881A (ja) Xi因子の治療学的使用
ES2913934T3 (es) Un producto de sustitución del factor de coagulación de la sangre para su uso en el tratamiento o la profilaxis de las hemorragias
US20240199703A1 (en) Procoagulant peptides and use thereof
EP4028046B1 (en) Methods of treatment related to complexes of von willebrand factor and complement c1q
HK40077326A (en) Methods of treatment related to complexes of von willebrand factor and complement c1q
HK40077326B (en) Methods of treatment related to complexes of von willebrand factor and complement c1q
MXPA06005477A (en) Therapeutic use of factor xi